DelveInsight's "LUXTURNA Market Size, Forecast, and Market Insight Report" highlights the details around LUXTURNA, a one-time ...

The Food and Drug Administration (FDA) has approved Tremfya ® (guselkumab) for the treatment of adults with moderately to severely active Crohn disease (CD).

LUXTURNA has significant market potential due to the high unmet need for effective treatments in rare genetic conditions. With its FDA approval for specific mutations in the RPE65 gene, it offers ...

In downstream processing of biopharmaceutical products, protein aggregation presents one of the main risks in terms of ...

BMS says it is combining AI and machine learning with its researchers’ expertise in drug targets and mechanisms of action, to ...

Findings from the Phase 3 BRAVE-AA-PEDS study were presented in ... announced the launch of 7.5 mg and 10 mg Zepbound (tirzepatide) single-dose vials, available for $499 with the new Zepbound ...

The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...

Bottles of over-the-counter Benadryl sold on Amazon are being recalled nationwide because they pose a safety risk to children ...

STEQEYMA® (ustekinumab-stba) is Celltrion's biosimilar to STELARA® (ustekinumab), which was launched on March 12, 2025 ...

The approval of gepotidacin (Blujepa; GSK) introduces the first new class of oral antibiotics for uncomplicated urinary tract ...

The global medical thawing system market was valued at $165.82 million in 2019 and is expected to reach $279.17 million by 2027 with a CAGR of 11.6% during the forecast period. Increase in incidences ...